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Abstract
Background: Chronic inflammation of the arterial wall is a key element in the pathogenesis of atherosclerosis, yet the
factors that trigger and sustain the inflammation remain elusive. Inflammasomes are cytoplasmic caspase-1-activating
protein complexes that promote maturation and secretion of the proinflammatory cytokines interleukin(IL)-1b and IL-18.
The most intensively studied inflammasome, NLRP3 inflammasome, is activated by diverse substances, including crystalline
and particulate materials. As cholesterol crystals are abundant in atherosclerotic lesions, and IL-1b has been linked to
atherogenesis, we explored the possibility that cholesterol crystals promote inflammation by activating the inflammasome
pathway.
Principal Findings: Here we show that human macrophages avidly phagocytose cholesterol crystals and store the ingested
cholesterol as cholesteryl esters. Importantly, cholesterol crystals induced dose-dependent secretion of mature IL-1b from
human monocytes and macrophages. The cholesterol crystal-induced secretion of IL-1b was caspase-1-dependent,
suggesting the involvement of an inflammasome-mediated pathway. Silencing of the NLRP3 receptor, the crucial
component in NLRP3 inflammasome, completely abolished crystal-induced IL-1b secretion, thus identifying NLRP3
inflammasome as the cholesterol crystal-responsive element in macrophages. The crystals were shown to induce leakage of
the lysosomal protease cathepsin B into the cytoplasm and inhibition of this enzyme reduced cholesterol crystal-induced IL-
1b secretion, suggesting that NLRP3 inflammasome activation occurred via lysosomal destabilization.
Conclusions: The cholesterol crystal-induced inflammasome activation in macrophages may represent an important link
between cholesterol metabolism and inflammation in atherosclerotic lesions.
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Introduction
Chronic inflammation is recognized as a major driving force in
atherogenesis [1]. The sites of atherosclerotic plaque development
in the arterial wall are characterized by cholesterol accumulation
and infiltration of peripheral blood monocytes, which gradually
differentiate into macrophages. These cells of the innate immune
system are equipped with and activated through an arsenal of
receptors that detect pathogen-associated molecular patterns
(PAMPs) and endogenous danger signals (DAMPs). Once
activated, the monocytes and macrophages secrete a myriad of
cytokines that promote inflammation in the arterial wall [2], yet
the factors that trigger and maintain this cytokine release in
atherogenesis are not fully understood.
Both in vitro and in vivo data show that IL-1b is a potent pro-
atherogenic cytokine. In atherosclerotic coronary arteries, IL-1b
levels have been shown to correlate with disease severity [3], and
knocking out IL-1b in atherosclerosis-prone ApoE
2/2 mice leads
to attenuation of disease development [4]. Furthermore, IL-1b
promotes the secretion of many other cytokines and chemokines
and induces the expression of adhesion molecules, endothelin-1,
and inducible nitric oxide synthase in endothelial cells [5–7].
The production of IL-1b is subject to complex regulation [8]
and consequently, two separate signals are required to yield the
active proinflammatory cytokine. First, induction of IL-1b mRNA,
for example via stimulation of pattern recognition receptors, is
needed for synthesis of proIL-1b protein in cells. A second signal is
required for activation of caspase-1, a protease that cleaves proIL-
1b into its biologically active secreted form [9]. Caspase-1
activation, in turn, is mediated by cytosolic protein complexes
termed inflammasomes, which function in various immune cells
[10]. Several different inflammasomes have been described, of
which the NLRP3 (nucleotide-binding domain leucine-rich repeat
containing (NLR) family, pyrin domain containing 3) inflamma-
some has been the most intensively studied [11]. Activated NLRP3
receptors oligomerize and recruit caspase-1 through the adaptor
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the active NLRP3 inflammasome complex [11]. NLRP3 receptor
is activated by diverse substances, including pore-forming toxins
[12], extracellular ATP [12], viral DNA [13], inhaled particulates
[14], and gout-associated uric acid crystals [15]. The highly
variable structures of these substances suggest that NLRP3
receptor senses them indirectly and indeed, cellular stress signals
caused by the substances have been proposed as intermediate steps
in NLRP3 activation [11,16].
Cholesterol crystals are a common, yet largely unexplored
element present in atherosclerotic lesions. A sharp increase in the
incidence of cholesterol crystals is observed in human atheroscle-
rotic lesions as they progress from fatty streaks to more advanced
lesions [17,18]. It has been suggested that cholesterol crystalliza-
tion may alter the mechanical properties of atherosclerotic lesions
by inducing changes in lipid-pool stiffness and stability [19,20].
Only a few studies have addressed the mechanism of cholesterol
crystal formation in atherosclerotic lesions. Intracellular cholester-
ol crystal nucleation has been demonstrated in vitro in lipid-loaded
macrophage foam cells [21,22]. However, in human atheroscle-
rotic lesions cholesterol crystals are found only rarely within cells;
rather, they are typically embedded within the extracellular
matrix, suggesting that nucleation of cholesterol crystals is an
extracellular process [23]. As crystalline substances have been
shown to induce inflammasome activation [14,15,24], we
hypothesized that cholesterol crystals could contribute to athero-
genesis through activation of the inflammasome pathway.
Results
Macrophages phagocytose cholesterol crystals and store
crystal-derived cholesterol as cellular cholesteryl esters
First, we explored whether cultured human macrophages are
able to process crystalline cholesterol. For this purpose, we
crystallized unesterified cholesterol from hot ethanol to obtain
cholesterol crystals. Addition of the cholesterol crystals to culture
medium induced a dose-dependent increase in the cholesteryl ester
content of primary human monocyte-derived macrophages and
PMA-differentiated THP-1 macrophages (Fig. 1A). Inhibition of
cytoskeletal movements with cytochalasin D abrogated cholesterol
crystal-induced cholesteryl ester accumulation (Fig. 1B), suggesting
phagocytic uptake of the crystals.
To directly demonstrate that the cholesterol crystals were
internalized by macrophages, confocal reflection microscopy was
employed. Due to their organized molecular structure, cholesterol
crystals strongly reflect the light of the excitation laser. This
enables pinpointing of cholesterol crystals in thin (,0.7 mm)
optical sections of cells. Representative images of THP-1
macrophages incubated with cholesterol crystals are presented in
Figure 1C. Intracellular reflection signals, lacking a surrounding
cell membrane, were frequently detected in THP-1 macrophages
incubated with cholesterol crystals, indicating completion of
phagocytosis (Fig. 1C, panels i,ii). In the presence of cytochalasin
D, the cholesterol crystals remained extracellular, as evidenced by
the absence of cytoplasmic reflection signals (Fig. 1C, panels iii,iiii).
Together, these data demonstrate that macrophages actively
phagocytosed cholesterol crystals, were able to partially dissolve
them, and stored the crystal-derived unesterified cholesterol as
cellular cholesteryl esters.
Cholesterol crystals induce IL-1b secretion from human
monocytes and macrophages
Next, we analyzed whether cholesterol crystals can induce
cytokine secretion from monocytes and macrophages. In the
presence of the Toll-like receptor (TLR) 4 ligand lipopolysaccha-
ride (LPS), cholesterol crystals induced dose-dependent secretion
of IL-1b in primary human monocytes and macrophages (Fig. 2A–
B). Likewise, THP-1 macrophages exhibited a strong and rapid
IL-1b response to cholesterol crystals (Fig. 2C). However, in
contrast to the primary monocytes and macrophages, the IL-1b
response of THP-1 macrophages was LPS-independent. In
primary monocytes and macrophages, LPS induces proIL-1b
mRNA and protein, whereas in THP-1 cells, PMA treatment has
been shown to induce stable expression of IL-1b [25], thus
eliminating the need for an additional stimulus. The presence of
mature IL-1b (17 kDa) in the cell culture supernatants of
cholesterol crystal-treated THP-1 macrophages was further
verified by Western blot analysis (Fig. 2C, inset). Another member
of the IL-1 superfamily, IL-1a, shares a common receptor and
similar biological activities with IL-1b [26–28]. IL-1a can be
secreted both as a proform and a cleaved mature form [29], but
proteolysis of IL-1a is not mediated by caspase-1 [9]. We found
Figure 1. Macrophages accumulate cholesteryl esters when
incubated with cholesterol crystals (CHCs). (A) Primary macro-
phages and THP-1 macrophages were incubated with 0.1–2 mg/ml
CHCs and cholesteryl esters (CE) were measured from cellular lipid
extracts by TLC. (B) Cytochalasin D (cytD; 2 mM) was employed to block
cytoskeletal movements during a 16 h incubation of primary and THP-1
macrophages with CHCs (0.5 and 1.0 mg/ml, respectively). (C) THP-1
macrophages treated with CHCs 6 cytD were stained with fluorophore-
conjugated cholera toxin subunit B (cell membrane; red) and Hoechst
(nuclei; blue). The cells were imaged using confocal fluorescence
microscopy, combined with detection of CHCs by confocal reflection of
the 488 nm laser line (green) (panels i, iii). CHCs are indicated by arrows
in the bright field panels (ii, iiii). Scale bar 5 mm. Each experiment was
performed $4 times. The data are means 6 s.e.m. **=p,0.01,
compared to the control cells.
doi:10.1371/journal.pone.0011765.g001
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cholesterol crystals was negligible irrespective of the presence of
LPS (Fig. 2D), although LPS reportedly induces proIL-1a mRNA
in macrophages [30]. Along with IL-1b, tumor necrosis factor a
(TNFa) is a major pro-atherogenic inflammatory cytokine. Unlike
LPS, cholesterol crystals did not induce TNFa secretion (Fig. 2E).
Effect of cholesterol crystals and LPS on the expression of
inflammasome-related genes
The known crystalline inflammasome activators induce activa-
tion of the NLRP3 inflammasome [14,15,24]. Moreover, upregu-
lation of NLRP3 receptor mRNA was recently proposed as an
important checkpoint preceding NLRP3 inflammasome activation
[31]. Therefore we studied whether cholesterol crystals would
influence the expression of the inflammasome-related genes
NLRP3, NLRP1, CASP1 (caspase-1), and IL1B. Following exposure
to cholesterol crystals and LPS, relative expression of the target
genes in primary macrophages was analyzed by real-time
quantitative RT-PCR. TNFA and IL1A were included in the
analysis as positive controls for LPS-mediated induction of gene
expression.
TNFA and IL1A mRNAs were equally strongly induced in cells
stimulated with cholesterol crystals and LPS and in cells stimulated
with LPS alone, whereas cholesterol crystals alone induced only
minimal changes in their expression (Fig. 3 A–C). Regarding the
inflammasome-related target genes, we found that treatment with
cholesterol crystals together with LPS markedly increased the
expression of NLRP3, CASP1, and IL1B mRNAs relative to
unstimulated control cells, while the levels of NLRP1 mRNA
remained low (Fig. 3A). However, a similar expression pattern was
observed in cells stimulated with LPS alone (Fig. 3B) and
accordingly, cholesterol crystal treatment alone induced only a
minor increase in IL1B mRNA (Fig. 3C). Thus, the observed
increases in NLRP3, CASP1, and IL1B expression were solely
attributable to LPS, which confirms the important role of TLR
signaling in setting the stage for inflammasome activation.
Cathepsin B and potassium efflux are essential for
cholesterol crystal-induced inflammasome activation
Next, we studied the potential mechanisms of cholesterol
crystal-induced IL-1b secretion in THP-1 macrophages. Firstly,
caspase-1 inhibitor zYVAD-fmk abrogated cholesterol crystal-
induced IL-1b secretion, confirming that IL-1b maturation was
indeed inflammasome-driven (Fig. 4). Furthermore, the IL-1b
response was diminished by cytochalasin D, indicating that
phagocytosis of cholesterol crystals was required for inflammasome
Figure 2. Monocytes and macrophages respond to cholesterol crystals (CHCs) by IL-1b secretion. Primary monocytes (A), primary
macrophages (B,D,E), and THP-1 macrophages (C) were incubated with CHCs for 16 h, 24 h, and 8 h, respectively. LPS (1 mg/ml) was used as a co-
stimulant for the primary cells. Concentrations of cytokines were subsequently determined from cell culture supernatants. The inset in 2C verifies the
presence of mature 17 kDa IL-1b in cell culture supernatants of THP-1 macrophages by Western blotting. The data are means 6 s.e.m. from $4
experiments. *=p,0.05 and **=p,0.01, compared to untreated cells.
doi:10.1371/journal.pone.0011765.g002
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both NLRP3 and NLRP1 inflammasomes [32]. IL-1b response to
the crystals was eliminated at high extracellular potassium
concentrations (Fig. 4), indicating the involvement of potassium
efflux in cholesterol crystal-mediated inflammasome activation.
Moreover, leakage of the lysosomal cysteine protease cathepsin B
into the cytoplasm has been associated with activation of the
NLRP3 inflammasome [24], although the exact mechanism of
activation remains unknown. Cathepsin B inhibitor CA-074Me
[33–35] significantly reduced the IL-1b response (Fig. 4), suggest-
ing a role for cathepsin B and NLRP3 in cholesterol crystal-
induced inflammasome activation.
Cholesterol crystals promote destabilization of lysosomes
and cathepsin B leakage into the cytoplasm
The involvement of cathepsin B in cholesterol crystal-induced
inflammasome activation prompted us to study the effect of
cholesterol crystals on lysosomal integrity and cathepsin B
localization. To visualize cathepsin B activity in live THP-1
macrophages, we utilized a cell-permeable fluorescently labeled
cathepsin B substrate z-Arg-Arg-cresyl violet [36,37]. Acridine
orange staining was used to monitor lysosomal integrity. We found
that in unstimulated cells, cathepsin B staining was bright and
corresponded well to the punctuate lysosomal staining pattern seen
in acridine orange-stained cells (Fig. 5, panels i,ii). In cholesterol
crystal-treated cells, cathepsin B activity was markedly reduced
(Fig. 5, panel iii), suggesting leakage of cathepsin B into the
cytoplasm, where the enzyme is gradually inactivated by neutral
Figure 3. Analysis of inflammasome-related gene expression after exposure of cells to cholesterol crystals (CHCs). Primary
macrophages from 3 donors were incubated for 1–9 h with (A) 0.5 mg/ml CHCs and 1 mg/ml LPS, (B) with LPS alone, or (C) with CHCs alone.
Untreated control cells were included at each time point. After the incubation, mRNA levels were determined by real-time quantitative RT-PCR. The
data are expressed as mean fold changes 6 s.e.m. relative to the untreated cells at each time point.
doi:10.1371/journal.pone.0011765.g003
Figure 4. Mechanism of cholesterol crystal (CHC)-induced IL-1b
secretion. THP-1 macrophages were incubated with CHCs in the
absence or presence of caspase-1 inhibitor zYVAD-fmk (25 mM),
cytochalasin D (2 mM), KCl (130 mM), or cathepsin B inhibitor CA-
074Me (10 mM). After the incubation, cell culture supernatants were
analyzed for IL-1b (average response to CHCs 662 pg/ml). The data are
means 6 s.e.m. from $5 experiments. **=p,0.01 and ***=p,0.001,
compared with CHC-treated cells.
doi:10.1371/journal.pone.0011765.g004
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orange signal in lysosomes was diminished by crystal treatment,
suggesting destabilization of the lysosomal membranes (Fig. 5,
panel iiii).
Cholesterol crystals activate the NLRP3 inflammasome
Collectively, the data implied involvement of the NLRP3
inflammasome in cholesterol crystal-induced IL-1b response. To
verify this, expression of NLRP3 receptor, the crucial component
in NLRP3 inflammasome, was silenced in THP-1 macrophages
using a combination of two small interfering RNAs (siRNAs). The
siRNA treatment reduced NLRP3 expression by 72%, while
negative control siRNA had no effect (Fig. 6A). Importantly,
silencing of NLRP3 gene completely abolished cholesterol crystal-
induced IL-1b secretion, while no significant inhibition of IL-1b
secretion was observed in cells transfected with negative control
siRNA (Fig. 6B). This effect of the NLRP3 siRNA was not due to
reduction in cholesterol crystal-induced lysosomal destabilization,
as cholesterol crystal-induced cathepsin B leakage to cytoplasm
was equally extensive in macrophages transfected with NLRP3
siRNA compared to untransfected macrophages (Fig. S1). These
data confirm the role of NLRP3 receptor as the cholesterol crystal-
responsive mediator of inflammasome assembly in human
macrophages.
Discussion
Cholesterol crystals formed in atherosclerotic lesions have
been traditionally considered an inert material and solely an
epiphenomenon of the disease. However, the present data argue
that cholesterol crystals may have a significant proinflammatory
role in atherogenesis. We show here that cholesterol crystals
induce inflammasome activation and secretion of the highly
proinflammatory cytokine IL-1b in human macrophages. This
novel mode of macrophage activation in atherosclerotic lesions
may represent a significant source of inflammation in the
affected tissue.
Earlier studies on macrophage-cholesterol crystal interaction
have suggested sequestration of cholesterol crystals in surface-
connected compartments [38], as well as complete phagocytosis of
the crystals [39]. We showed by confocal reflection microscopy
that human macrophages phagocytose cholesterol crystals and,
despite their relatively large size, are able to fully internalize the
crystals. Moreover, phagocytosis of cholesterol crystals led to
accumulation of cellular cholesteryl esters in macrophages. These
observations indicate that macrophages possess the capacity to
remove, at least to some extent, the cholesterol crystals deposited
in atherosclerotic lesions. Importantly, we showed that phagocy-
tosed cholesterol crystals can elicit an inflammatory reaction by
triggering macrophage IL-1b secretion. The IL-1b response to
cholesterol crystals was caspase-1-dependent, indicating inflam-
masome-mediated molecular mechanisms. Indeed, siRNA silenc-
ing experiments confirmed NLRP3 receptor, the initiator of
NLRP3 inflammasome assembly, as the cholesterol crystal-
responsive element in macrophages. These observations imply
that cholesterol crystals formed in atherosclerotic lesions may not
Figure 5. Cholesterol crystals (CHCs) cause destabilization of
lysosomes and leakage of cathepsin B into the cytoplasm. CHC-
treated or untreated live THP-1 macrophages were stained with
cathepsin B substrate z-Arg-Arg-cresyl violet (panels i, iii) or with
acridine orange (panels ii, iiii). The fluorescent cresyl violet group of z-
Arg-Arg-cresyl violet is dequenched upon cleavage of one or both of
the arginines by cathepsin B. Acridine orange aggregates in the acidic
pH of lysosomes, which changes the fluorescence emission of the dye
from green to red. The images are representative of 3 experiments.
doi:10.1371/journal.pone.0011765.g005
Figure 6. Silencing of NLRP3 attenuates cholesterol crystal
(CHC)-induced IL-1b secretion. (A) NLRP3 mRNA levels were
reduced by 72% after treatment of THP-1 macrophages with NLRP3-
targeted small interfering RNA (siRNA). (B) CHC-induced IL-1b secretion
was abolished after treatment of cells with NLRP3 siRNA, whereas
treatment of cells with negative control siRNA had no effect. The data
are means 6 s.e.m. from 5 (A) and 3 (B) experiments. **=p,0.01.
doi:10.1371/journal.pone.0011765.g006
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strong inflammatory reaction.
The NLRP3 receptor can be activated by diverse agents, such
as extracellular ATP [12], inhaled silica and asbestos [14,24], and
endogenously formed monosodium urate crystals [15]. Potassium
efflux [32], leakage of lysosomal cathepsin B into the cytoplasm
[24], and/or reactive oxygen species formation [14] caused by
these substances seem to be essential intermediate steps in
activation of NLRP3 receptor, although the interplay between
these processes is poorly understood [11,16]. Our data suggest
that both potassium efflux and cathepsin B activity contribute to
cholesterol crystal-mediated activation of the NLRP3 inflamma-
some. Further studies are required to elucidate the possible
interconnection and relative importance of these cellular factors
in cholesterol crystal-induced NLRP3 activation. It is important
to note, however, that some uncertainty exists regarding
selectivity of the cathepsin B inhibitor CA-074Me used in these
experiments [33–35]. It has been shown that in murine
fibroblasts CA-074Me inhibits the activity of both cathepsin B
and the very closely related cathepsin L [40]. We thus conclude
that both cathepsins B and L may be involved in triggering
NLRP3 activation in response to cholesterol crystals. Of interest,
protein levels of both cathepsin B and L are elevated in
atherosclerotic plaques compared to normal arterial tissue, and
colocalization with macrophage markers is observed for both
cathepsins [41,42].
Because of its proIL-1b-inducing effect, LPS-priming of primary
macrophages was essential for cholesterol crystal-induced IL-1b
secretion. Several lines of evidence indicate that TLR signaling is
operative in atherosclerotic arterial intima, and may contribute to
disease pathogenesis [43,44]. In addition to TLRs, an abundance
of TLR ligands, both bacterial [45] and endogenous [46–49], has
been demonstrated in atherosclerotic lesions. Considering these
observations, it is conceivable that cholesterol crystals, in concert
with proatherogenic TLR ligands, can elicit inflammasome
activation in the lesions. This is further supported by the finding
that caspase-1 mRNA and protein can be found in human
atherosclerotic lesions, while they are virtually absent in normal
arteries [50].
Taken together, the present findings demonstrate that
cholesterol crystals, common constituents of atherosclerotic
lesions, induce NLRP3 inflammasome activation and IL-1b
secretion in human macrophages. The suggested mechanism of
NLRP3 activation by cholesterol crystals involves both potassium
efflux and cathepsin B leakage into the cytoplasm (Fig. 7). In
atherosclerosis, the inflammasome-mediated IL-1b release would
promote an inflammatory milieu and thus drive lesion progres-
sion. Consequently, the cholesterol crystal-induced inflamma-
some activation may represent an important link between
cholesterol metabolism and inflammation in atherosclerotic
lesions.
While this study was being finalized, Duewell and colleagues
published a similar study reporting that cholesterol crystals
activate the NLRP3 inflammasome in mouse macrophages
through a lysosomal damage- and cathepsin-mediated mecha-
nism [51]. Our study shows that the same activation pathway of
NLRP3 is functional also in human macrophages exposed to
cholesterol crystals. Furthermore, Duewell and colleagues
showed that cholesterol crystals can be detected already at an
early stage of disease development in the atherosclerotic
ApoE
2/2 mouse model. Altogether, the results by Duewell et
al. and the results of the present study strongly implicate
cholesterol crystals as a potential source of inflammation in
atherosclerotic lesions.
Materials and Methods
Ethics statement
Buffy coats were obtained from healthy human donors after
informed consent as by-products from the preparation of blood
products for clinical use (Red Cross Finland Blood Service,
Helsinki, Finland).
Cell culture
Buffy coats were obtained from healthy human donors (Red
Cross Finland Blood Service, Helsinki, Finland). Monocytes were
isolated and differentiated into macrophages as described [52],
except that recombinant human macrophage colony-stimulating
factor (M-CSF, 50 ng/ml; Nordic Biosite, Ta ¨by, Sweden) was
used instead of GM-CSF. Human monocytic leukaemia cell line
THP-1 was obtained from the American Type Culture Collection
(Manassas, VA; cat. TIB-202) and maintained in RPMI 1640
supplemented with 2 mM L-glutamine, 10% fetal bovine serum,
25 mM HEPES, 100 U/ml penicillin, and 100 mg/ml streptomy-
cin (standard THP-1 medium). To induce monocyte-to-macro-
phage differentiation, the THP-1 cells were cultured for 72 h in
the standard culture medium supplemented with 100 nM phorbol
12-myristate 13-acetate (PMA; Sigma-Aldrich, St. Louis, MO).
Preparation of cholesterol crystals
Cholesterol (Sigma, Saint Louis, MO; cat. C8667) dissolved in
95% ethanol (12.5 g/l) was heated to 60uC, filtered through
Whatman filter paper while still warm, and left at room
temperature to allow crystallization to proceed [53]. Flat,
rhomboid, and relatively large (1–5 mm) cholesterol crystals were
formed. The crystals were collected by filtering, autoclaved,
ground using a sterile mortar and a pestle to yield a size range of
1–10 mm, and stored at 220uC until use. Endotoxin was not
detected in the crystals by Limulus Amebocyte Lysate QCL-1000
assay (Lonza/Cambrex, Walkersville, MD).
Figure 7. Proposed mechanism of cholesterol crystal (CHC)-
induced inflammasome activation. CHCs are phagocytosed by
macrophages, causing lysosomal destabilization and leakage of
cathepsin B to cytoplasm, where the enzyme indirectly activates the
NLRP3 inflammasome. Lowering of intracellular potassium concentra-
tion, stemming from potassium efflux caused by phagocytosed CHCs, is
also required for NLRP3 activation.
doi:10.1371/journal.pone.0011765.g007
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Primary monocytes and macrophages (1.5610
6 mononuclear
cells/well, of which ,20% are monocytes) and THP-1 macro-
phages (3610
5 cells/well) were cultured on 24-well plates and
subjected to cholesterol crystals for 4–24 h at +37uC under 5%
CO2 in a serum-free culture medium. Where indicated, also 1 mg/
ml LPS from E.coli (Sigma; serotype 0111:B4), 25 mM caspase-1
inhibitor z-YVAD-fmk (Santa Cruz Biotechnology, Santa Cruz,
CA), 2 mM cytochalasin D (Sigma), 10 mM cathepsin B inhibitor
CA-074Me (Calbiochem), or 130 mM KCl was added to the
incubation medium. After the incubations, culture media were
collected for analysis of their cytokine contents and the cells were
washed with PBS and subjected to lipid extraction or RNA
isolation as described below.
Lipid extraction and analysis by thin layer
chromatography
Cellular lipids were extracted from the cells with hexane-
isopropanol (3:2, v/v). The solvent was evaporated and the lipids
were redissolved in chloroform-methanol (2:1, v/v). The samples
were then applied onto silica-coated thin layer chromatography
(TLC) plates (CAMAG, Berlin, Germany) using an automatic
TLC sampler (Sampler3; CAMAG). Hexane/diethyl ether/
concentrated acetic acid/H2O (130:30:2:0.5, v/v) was used as
the mobile phase for TLC analysis of cholesterol ester content in
the samples. The lipids were visualized by dipping the TLC plate
into CuSO4 (3%)/H2PO4 (8%) and by subsequently heating the
plate for 10 min at 150uC. The bands were scanned with TLC
Scanner3 (CAMAG) and analyzed using TLC Evaluation
Software (CAMAG).
Analysis of cytokine secretion
IL-1b, IL-1a, and TNFa were analyzed from the culture media
samples using commercial enzyme-linked immunosorbent assays
(ELISA) according to the manufacturer’s protocols (all ELISAs
were from R&D Systems, Minneapolis, MN).
Western blotting
Culture medium supernatants from cholesterol crystal-treated
(1 mg/ml, 24 h) THP-1 macrophages were concentrated and
purified using Amicon Ultra-15 centrifugal filter devices (10 kDa
cut-off; Millipore, Bedford, MA) and 2-D Clean-Up Kit (GE
Healthcare Life Sciences, Uppsala, Sweden). A culture medium
sample corresponding to 1.5610
6 cells was run in polyacrylamide
gel electrophoresis and transferred to an Immobilon-P Transfer
Membrane (Millipore). The polyclonal anti-IL-1b antibody used
for detection has been described previously [54].
NLRP3 knock-down with small interfering RNA (siRNA)
THP-1 cells were seeded on 12-well plates (1.5610
5 cells/well)
in the standard THP-1 culture medium supplemented with 50 nM
PMA. After 24 hours, the cells were transfected with 100 nM total
siRNA targeted at NLRP3 (also known as CIAS1) mRNA
(Hs_CIAS1_6 and Hs_CIAS1_9 siRNAs at 1:1 molar ratio;
Qiagen, Valencia, CA) or with 100 nM AllStars Negative Control
siRNA (Qiagen), using the HiPerFect transfection reagent
(Qiagen) according to the manufacturer’s instructions. After 22 h
of incubation with the siRNAs, the cells were washed with PBS
and incubated for a further 12 h in serum-free THP-1 medium
without or with 1 mg/ml cholesterol crystals. Finally, the media
were collected and RNA was isolated from the cells for
quantitative real-time PCR.
Quantitative real-time RT-PCR
Total cellular RNA was purified from the cells using RNeasy
columns (Qiagen). RNA from each sample (0.25–0.5 mg) was
converted to cDNA using MMLV reverse transcriptase and
random hexamers (Promega, Madison, WI, USA). The cDNA was
amplified in duplicate using TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA) with gene-specific primers
and probes (Table 1) on ABI PRISM 7500 sequence detector
system (Applied Biosystems, Foster City, CA). The data were
developed with Sequence Detector System software (version 1.4,
Applied Biosystems) and the threshold value (Ct) of a sample was
selected according to the manufacturer’s guidelines. For data
normalization, an endogenous control (18S rRNA) was deter-
mined for controlling the cDNA input and the relative units were
calculated by a comparative Ct method [55].
Fluorescence imaging of cathepsin B and lysosomes
Cholesterol crystal-treated THP-1 macrophages were stained with
cell-permeable fluorescently labeled cathepsin B substrate z-Arg-Arg-
cresyl violet and Hoechst stain or with 5 mM acridine orange (AO)
according to the manufacturer’s instructions (CV-Cathepsin B
Detection Kit by BIOMOL, Plymouth Meeting, PA). The coverslips
containing the stained live cells were then mounted in a drop of PBS
and examined within 30 min using an epifluorescence microscope.
Confocal reflection microscopy
THP-1 macrophages were treated with cholesterol crystals in
the absence or presence of cytochalasin D. The nuclei were then
Table 1. Primers and probes used in quantitative real-time
RT-PCR.
Primer or
fluorogenic probe Sequence
IL1B-F* 59-TTACAGTGGCAATGAGGATGAC -39
IL1B-R
# 59- GTCGGAGATTCGTAGCTGGAT -39
IL1B probe 59-FAM-AACAGATGAAGTGCTCCTTCCAGGACC-BHQ1-39
IL1A-F 59-ATCAGTACCTCACGGCTGCTG-39
IL1A-R 59-TGGGCAGTCACATACAATTGAGT-39
IL1A probe 59-FAM-CCCATGTCAAATTTCACTGCTTCATCCA-BHQ1-39
TNFA-F 59- GCTGCACTTTGGAGTGATCG-39
TNFA-R 59- GTTTGCTACAACATGGGCTACAG-39
TNFA probe 59-FAM- CCCAGGCAGTCAGATCATCTTCTCGA-BHQ1-39
CASP1-F 59- CCGAAGGTGATCATCATCCA-39
CASP1-R 59- ATAGCATCATCCTCAAACTCTTCTG-39
CASP1 probe 59-FAM-CCTGCCGTGGTGACAGCCCTG-BHQ1-39
NLRP1-F 59-GGAGGCCTTGGTGAAACC-39
NLRP1-R 59-CGATGTCACTCGGGCTATCA-39
NLRP1 probe 59-FAM- CAGCCCGCATAGCCGTACCTTCA-BHQ1-39
NLRP3-F 59-GGAGAGACCTTTATGAGAAAGCAA-39
NLRP3-R 59-GCTGTCTTCCTGGCATATCACA-39
NLRP3 probe 59-FAM-ACGTGCATTATCTGAACCCCACTTCGG-BHQ1-39
18S-F 59-CGGCTACCACATCCAAGGAA-39
18S-R 59-GCTGGAATTACCGCGGCT-39
18S probe 59-FAM-TGCTGGCACCAGACTTGCCCTC-BHQ1-39
*forward primer.
#reverse primer.
doi:10.1371/journal.pone.0011765.t001
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ganglioside GM1 with 12 mg/ml cholera toxin subunit B Alexa
Fluor647 conjugate (CTXb-647; Molecular Probes, Eugene, OR)
for 30 min at +4uC [56,57]. Finally, the cells were fixed and the
coverslips were mounted on glass slides. Images were acquired
using LSM 510 Meta confocal laser scanning microscope (Carl
Zeiss AG, Go ¨ttingen, Germany) with a 636Plan-Apochromat oil
immersion objective (NA=1.4). Fluorescence signals from
Hoechst and CTXb-647 were captured simultaneously with the
reflection signal (excitation 488 nm, detector channel set to 475–
525 nm) from cholesterol crystals.
Statistics
Calculations were performed with PASW Statistics 17.0 (SPSS
Inc., Chicago, IL) using the non-parametric Mann-Whitney’s U-
test. Data are presented as means 6 standard error of the mean
(s.e.m.). Statistical significance was set to p,0.05.
Supporting Information
Figure S1 NLRP3 siRNA treatment does not reduce cholesterol
crystal (CHC)-induced lysosomal destabilization. THP-1 macro-
phages were transfected with NLRP3 siRNA or left untreated.
The cells were subsequently exposed to 1 mg/ml of cholesterol
crystals for 6 h and stained with the fluorescently labeled cathepsin
B substrate z-Arg-Arg-cresyl violet (red) and nuclear Hoechst stain
(blue). For detailed protocols, refer to the materials and methods
section. In control cells that received neither siRNA nor CHCs (A)
cathepsin B activity localized to abundant small cytoplasmic
vesicles in agreement with a lysosomal localization. In cells treated
with CHCs alone (B) or with NLRP3 siRNA and CHCs (C)
cathepsin B activity was markedly reduced indicating leakage of
cathepsin B to cytoplasm where the enzyme is gradually
inactivated by neutral pH.
Found at: doi:10.1371/journal.pone.0011765.s001 (5.11 MB TIF)
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